Financial
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Werfen
HQ Spain · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Not assessed
Customer rating
No reviews yet
Financial health
Band: Not assessedPrivately held
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
No adverse media involving Werfen found in HSH's search of the last 24 months.
Cyber & information governance
No data breaches, cyber incidents or regulator action involving Werfen found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
May 2026: Werfen's US unit (Instrumentation Laboratory) began a Class 2 FDA recall of GEM Premier 5000 bar code reader wands after a software change could assign results to the wrong patient ID.
Contract performance
Jun 2025: Werfen won NHS Blood and Transplant's secondary donor testing contract, which the company says makes it the sole provider of secondary donor screening across all four UK blood services.
Competitors
No competitors linked yet.